The Latest Breaking News from Novavax

WHO recommends R21/Matrix-M malaria vaccine developed by Oxford and Serum Institute of India. Vaccine has met safety, quality and effectiveness standards. Serum Institute has established production capacity for 100 million doses/annum. Vaccine efficacy over 12 months is 75% at sites with high seasonal malaria transmission and 68% at sites with…

All Americans ages 6 months and older are eligible for the new jabs, the CDC said Tuesday.

On Sept. 12, 2023, the Centers for Disease Control and Prevention recommended the newly formulated COVID-19 vaccines for all Americans ages 6 months and up, hours after its expert advisory committee voted 13 to 1 in favor of recommending the vaccines.

Chicago public health officials have said the CDC approval was all they needed to “begin the rollout” of the vaccine, which will be free for all city residents. “We already have the vaccine in Chicago,” Dr. Geraldine Luna, medical director for the Chicago Department of Public Health, said Monday.

Americans may soon be able to get an updated COVID-19 vaccine

Novavax stock crumbled Monday after the Food and Drug Administration signed off on updated Covid boosters from rivals Pfizer and Moderna.

The FDA approved reformulated COVID-19 vaccines from Pfizer and Moderna, but deferred an expected authorization for Novavax’s vaccine.

Pfizer stock and Moderna stock dipped Friday — giving back some of their late Thursday gains on an upswing related to their updated Covid shots.

Vaccine manufacturers like Pfizer/BioNTech, Moderna, and Novavax are switching up their shots in preparation for the new season.

The biggest names in Covid are updating their vaccines for a fall campaign, but that might not bolster Pfizer stock and Moderna stock.

COVID-19 shots should be reformulated to target an XBB subvariant of the highly infectious omicron strain to provide the best protection during the U.S. fall and winter season, health regulators said.